



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/537,743	11/09/2006	Roberto A. Macina	DEX-0552	4777
32800 7590 09/24/2008 LICATA & TYRRELL P.C. 66 E. MAIN STREET MARLTON, NJ 08053				
EXAMINER MARTINELL, JAMES				
ART UNIT		PAPER NUMBER		
1634				
NOTIFICATION DATE		DELIVERY MODE		
09/24/2008		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

poreilly@licataandtyrrell.com

Office Action Summary

Application No.

10/537,743

Applicant(s)

MACINA ET AL.

Examiner

James Martinell

Art Unit

1634

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 August 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) 11-14 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-10 and 15-18 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 06 June 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/S508)
Paper No(s)/Mail Date 6/6/05 & 12/3/07.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
- 5) ☐ Notice of Informal Patent Application.
- 6) ☐ Other: _____.

Applicant's election with traverse of the requirement for restriction in the reply filed on August 19, 2008 is acknowledged. The traversal is on the ground(s) that a search of the art relating to an elected nucleic acid should reveal art relating to all claims. This is not found persuasive because the searches of the three Groups of inventions are not co-extensive. It is noted that applicants did not argue against the selection of a single sequence for examination on the merits.

The requirement is still deemed proper and is therefore made FINAL.

Claims 11-14, 15 (insofar as it is drawn to polypeptide assays) and 16-18 (insofar as they are drawn to kits containing polypeptides (claim 16), methods of treatment using polypeptides (claim 17), and polypeptide vaccines (claim 18)) are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on August 19, 2008.

No copy of WO 042393, cited in the Information Disclosure Statement filed December 3, 2007, is in the file. However, since the reference was readily available to the USPTO, it has been considered.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-10 and 15-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are vague and indefinite.

- (a) Claims 1-10 and 15-18 are vague and indefinite because they claim more than was elected. Claims 1, 15, 16, and 17 are drawn to or require the use of more than one selected nucleic acid sequence. Claims 15, 16, and 18 are

drawn to non-elected methods of using polypeptides, Kits containing polypeptides, and polypeptide vaccines.

- (b) Claims 1, 15, and 17 are vague and indefinite because one cannot know any particular percent sequence identity to a nucleic acid that encodes a given polypeptide sequence because of the degeneracy of the genetic code.

Claims 1-10 and 15-18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Because one cannot know any particular percent sequence identity to a nucleic acid that encodes a given polypeptide sequence because of the degeneracy of the genetic code, the claims lack an adequate written description in that not enough structure is recited such that one of skill in the art would consider applicants to be in possession of the claimed invention as of the effective filing date of the claims.

In *Vas-Cath v. Mahurkar*, 19 USPQ2d 1111 (Fed. Cir. 1991) the court stated, "applicant must also convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*" (emphasis in the original) (*Vas-Cath* at page 1117). The instant application does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is now claimed" (*Vas-Cath* at page 1116). In *Fiers v. Sugano*, 25 USPQ2d 1601 (Fed. Cir. 1993), the court also held that, "An adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference a potential method for isolating it; what is required is a description of the DNA itself" (*Fiers v. Sugano*, page 1606). This view was reiterated in *Fiddes v. Baird*, USPQ2d 1481 (BPAI 1993) at page 1483, "If a conception of a DNA requires a specific definition, such as by structure, formula, chemical name, or physical properties, as we have held, then a description also requires that degree of specificity. . . . one cannot describe what one has not conceived." The court amplified this

Art Unit: 1634

notion with respect to inventions claiming genetic material in *Regents of the University of California v. Eli Lilly*, 43 USPQ2d 1398 (Fed. Cir. 1997), stating at page 1406,

"In claims to genetic material, however, a generic statement such as 'vertebrate insulin cDNA' or 'mammalian insulin cDNA,' without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art therefore cannot, as one can do with a fully described genus, visualize or recognize the identity of the members of the genus. . . . Accordingly, naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material."

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-10 and 15-18 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Mitcham et al (WO 00/36107 (June 23, 2000)). Mitcham et al discloses a nucleic acid (SEQ ID NO: 391) that hybridizes to SEQ ID NO: 109 of the instant application (see the alignment below). Mitcham et al also teaches the use of the nucleic acid as a marker for ovarian cancer, treatment of ovarian cancer, and kits for the detection of ovarian cancer (*e.g.*, see the Abstract, page 28, line 15 through page 29, line 20, page 37, lines 11-23, page 42, line 25 through page 44, line 9, page 45, lines 3-10, and page 46, line 1 through page 51, line 20). SEQ ID NO: 109 has basis in Serial No. 60/484,584 (sequence bridging pages 154-155) and thus the effective filing date of the instant claims is June 30, 2003.

Art Unit: 1634

ALIGNMENT OF SEQ ID NO: 109 AND MITCHAM ET AL (WO 00/35107, SEQ ID NO: 391)

RESULT 2

AAA70077

ID AAA70077 standard; cDNA; 2627 BP.

XX

AC

AAA70077;

XX

DT

07-NOV-2000 (first entry)

XX

DE

Human ovarian carcinoma antigen polynucleotide SEQ ID NO:391.

XX

KW

Human; ovarian carcinoma; ovarian cancer; therapy; diagnosis;

KW

tumour antigen; identification; cytostatic; gene therapy; vaccine; ss.

XX

OS

Homo sapiens.

XX

PN

WO200036107-A2.

XX

PD

22-JUN-2000.

XX

PF

17-DEC-1999; 99WO-US030270.

XX

PR

17-DEC-1998; 98US-00215681.

PR

17-DEC-1998; 98US-00216003.

PR

23-JUN-1999; 99US-00338933.

PR

24-SEP-1999; 99US-00404879.

XX

FA

(CORI-) CORIXA CORP.

XX

FI

Mitcham JL, King GE, Algate PA, Frudakis TN;

XX

DR

WPI; 2000-431589/37.

XX

PT

Immunogenic portion of an ovarian carcinoma protein and the nucleic acid

PT

encoding it, useful for the diagnosis, prevention and treatment of

PT

cancer, preferably ovarian cancer.

XX

PS

Claim 1; Page 204-205; 299pp; English.

XX

CC

The present invention describes an isolated polypeptide comprising an

CC

immunogenic portion of an ovarian carcinoma protein (or its variants).

CC

Ovarian carcinoma proteins, and polynucleotides encoding them, have

CC

cytostatic activity and can be used in gene therapy and vaccines. Ovarian

CC

carcinoma polypeptides, nucleic acids, antibodies and vaccines are useful

CC

for the prevention, diagnosis and treatment of cancer, preferably ovarian

CC

cancer. AAA69691 to AAA70077 and AAB12552 to AAB12557 represent human

CC

ovarian carcinoma polynucleotides and proteins used in the

CC

exemplification of the present invention

XX

SQ

Sequence 2627 BP; 754 A; 605 C; 584 G; 684 T; 0 U; 0 Other;

Art Unit: 1634

Query Match		90.5%; Score 2434; DB 3; Length 2627;					
Best Local Similarity		100.0%; Pred. No. 0;					
Matches 2434; Conservative		0; Mismatches		0; Indels		0; Gaps	
Qy	257	CAGGGAGACACTCCATCACAGTCACTACTGTGCGCTCAGCTGGGAACATTGGGGAGGATG	316				
Db	177	CAGGGAGACACTCCATCACAGTCACTACTGTGCGCTCAGCTGGGAACATTGGGGAGGATG	236				
Qy	317	GAATCCTGAGCTGCACTTTTGAACCTGACATCAAACCTTCTGATATCGTGATACAATGGC	376				
Db	237	GAATCCTGAGCTGCACTTTTGAACCTGACATCAAACCTTCTGATATCGTGATACAATGGC	296				
Qy	377	TGAAGGAAGGTGTTTATAGGCTTGGTCCATGAGTTCAAAGAAGGCAAGATGAGCTGTCCG	436				
Db	297	TGAAGGAAGGTGTTTATAGGCTTGGTCCATGAGTTCAAAGAAGGCAAGATGAGCTGTCCG	356				
Qy	437	AGCAGGATGAAATGTTTCAAGGCGGACAGCAGTGTGCTGATCAAGTGATAGTTGGCA	496				
Db	357	AGCAGGATGAAATGTTTCAAGGCGGACAGCAGTGTGCTGATCAAGTGATAGTTGGCA	416				
Qy	497	ATGCCTCTTTGCGGCTGAAAAACGTGCAACTCACAGATGCTGGCACTACAAATGTTATA	556				
Db	417	ATGCCTCTTTGCGGCTGAAAAACGTGCAACTCACAGATGCTGGCACTACAAATGTTATA	476				
Qy	557	TCATCACTTCTAAAGGCAAGGGGAATGCTAACCTTGAGTATAAACTGGAGCCTTCAGCA	616				
Db	477	TCATCACTTCTAAAGGCAAGGGGAATGCTAACCTTGAGTATAAACTGGAGCCTTCAGCA	536				
Qy	617	TGCCGGAAGTGAATGTGGACTATAATGCCAGCTCAGAGACCTTGCAGGTGTGAGGCTCCCC	676				
Db	537	TGCCGGAAGTGAATGTGGACTATAATGCCAGCTCAGAGACCTTGCAGGTGTGAGGCTCCCC	596				
Qy	677	GATGGTTCCCCCAGCCACAGTGGTCTGGGCATCCCAAGTTGACCAAGGAGCCAACTTCT	736				
Db	597	GATGGTTCCCCCAGCCACAGTGGTCTGGGCATCCCAAGTTGACCAAGGAGCCAACTTCT	656				
Qy	737	CGGAAGTCTCCAATACAGCTTTGAGCTGAACTCTGAGAATGTGACCATGAAGTTTGTGT	796				
Db	657	CGGAAGTCTCCAATACAGCTTTGAGCTGAACTCTGAGAATGTGACCATGAAGTTTGTGT	716				
Qy	797	CTGTGCTCTACAATGTTACGATCAACAACACATACCTCTGTATGATTGAAAATGACATTG	856				
Db	717	CTGTGCTCTACAATGTTACGATCAACAACACATACCTCTGTATGATTGAAAATGACATTG	776				
Qy	857	CCAAAGCAACAGGGGATATCAAAGTGACAGAATCGGAGATCAAAGGCGGAGTCACCTAC	916				
Db	777	CCAAAGCAACAGGGGATATCAAAGTGACAGAATCGGAGATCAAAGGCGGAGTCACCTAC	836				
Qy	917	AGTGTCTAAACTCAAAGGCTTCTCTGTGTCTCTTCTTTTCCATCAGCTGGGCAC	976				
Db	837	AGTGTCTAAACTCAAAGGCTTCTCTGTGTCTCTTCTTTTCCATCAGCTGGGCAC	896				
Qy	977	TTCTGCCTCTCAGCCCTTACCTGATGCTAAAAAATGTGCCTTGGCCACAAAAAAGCATG	1036				
Db	897	TTCTGCCTCTCAGCCCTTACCTGATGCTAAAAAATGTGCCTTGGCCACAAAAAAGCATG	956				
Qy	1037	CAAAGTCATTGTTACAACAGGGATCTACAGAATAATTTACCAACCAGATATGACCTAGTT	1096				
Db	957	CAAAGTCATTGTTACAACAGGGATCTACAGAATAATTTACCAACCAGATATGACCTAGTT	1016				

Art Unit: 1634

Qy	1097	TTATATTTCTGGGAGGAAATGAATTCATATCTAGAAGTCTGGAGTGAGCAAAACAAGAGCA	1156
Db	1017	TTATATTTCTGGGAGGAAATGAATTCATATCTAGAAGTCTGGAGTGAGCAAAACAAGAGCA	1076
Qy	1157	AGAAACAAAAGAAGCCAAAAGCAGAGGCTCCAATATGAACAAGATAAATCTATCTTCA	1216
Db	1077	AGAAACAAAAGAAGCCAAAAGCAGAGGCTCCAATATGAACAAGATAAATCTATCTTCA	1136
Qy	1217	AAGACATATTAGAAAGTTGGGAAAATAATTCATGTGAAGTAGACAAAGTGTGTTAAGAGTGA	1276
Db	1137	AAGACATATTAGAAAGTTGGGAAAATAATTCATGTGAAGTAGACAAAGTGTGTTAAGAGTGA	1196
Qy	1277	TAAGTAAATGCACGTGGAGACAAAGTGCATCCCCAGATCTCAGGGACCTCCCCCTGCCTG	1336
Db	1197	TAAGTAAATGCACGTGGAGACAAAGTGCATCCCCAGATCTCAGGGACCTCCCCCTGCCTG	1256
Qy	1337	TCACCTGGGGAGTGAGAGGACAGGATAGTGCATGTTCTTTGTCTCTGAAATTTTAGTTAT	1396
Db	1257	TCACCTGGGGAGTGAGAGGACAGGATAGTGCATGTTCTTTGTCTCTGAAATTTTAGTTAT	1316
Qy	1397	ATGTGCTGTAATGTTGCTCTGAGGAAGCCCTGGAAAGTCTATCCCAACATATCCACATC	1456
Db	1317	ATGTGCTGTAATGTTGCTCTGAGGAAGCCCTGGAAAGTCTATCCCAACATATCCACATC	1376
Qy	1457	TTATATTCACAAAATTAAAGCTGTAGTATGTACCCCTAAGACGCTGCTAATTGACTGCCACT	1516
Db	1377	TTATATTCACAAAATTAAAGCTGTAGTATGTACCCCTAAGACGCTGCTAATTGACTGCCACT	1436
Qy	1517	TCGCAACTCAGGGCGGCTGCATTTTAGTAATGGGTCAAATGATTCACTTTTATGATGC	1576
Db	1437	TCGCAACTCAGGGCGGCTGCATTTTAGTAATGGGTCAAATGATTCACTTTTATGATGC	1496
Qy	1577	TTCCAAAGGTGCTTTGGCTTCTCTCCCAACTGACAAATGCCAAAGTTGAGAAAAATGAT	1636
Db	1497	TTCCAAAGGTGCTTTGGCTTCTCTCCCAACTGACAAATGCCAAAGTTGAGAAAAATGAT	1556
Qy	1637	CATAATTTTAGCATAAACAGAGCAGTCGGGCACACCGATTTTATAAATAAACTGAGCACC	1696
Db	1557	CATAATTTTAGCATAAACAGAGCAGTCGGGCACACCGATTTTATAAATAAACTGAGCACC	1616
Qy	1697	TTCTTTTAAACAAACAAATGCGGGTTTATTCTCAGATGATGTTATCCCGTGAATGGTC	1756
Db	1617	TTCTTTTAAACAAACAAATGCGGGTTTATTCTCAGATGATGTTATCCCGTGAATGGTC	1676
Qy	1757	CAGGGAAGGACCTTTACCTTTGACTATATGGCATTATGTCATCACAAGCTCTGAGGCTTC	1816
Db	1677	CAGGGAAGGACCTTTACCTTTGACTATATGGCATTATGTCATCACAAGCTCTGAGGCTTC	1736
Qy	1817	TCCTTTCCATCCTGCGTGGACAGCTAAGACCTCAGTTTTCATATAGCATCTAGAGCAGTGG	1876
Db	1737	TCCTTTCCATCCTGCGTGGACAGCTAAGACCTCAGTTTTCATATAGCATCTAGAGCAGTGG	1796
Qy	1877	GACTCAGCTGGGGTATTTCGCCCCCACTCCGGGGGAATGTCCTGAAGACAAATTTGGT	1936
Db	1797	GACTCAGCTGGGGTATTTCGCCCCCACTCCGGGGGAATGTCCTGAAGACAAATTTGGT	1856
Qy	1937	TACCTCAATGAGGGAGTGGAGGAGGATACAGTGCTACTACCAACTAGTGGATAAAGGCCA	1996
Db	1857	TACCTCAATGAGGGAGTGGAGGAGGATACAGTGCTACTACCAACTAGTGGATAAAGGCCA	1916

Art Unit: 1634

Qy 1997 GGGATGCTGCTCAACCTCCTACCATGTACAGGACGCTCCCCATTACAAC TACCCAATCC 2056
 |||
 Db 1917 GGGATGCTGCTCAACCTCCTACCATGTACAGGACGCTCCCCATTACAAC TACCCAATCC 1976
 |||

Qy 2057 GAAGTGTCAACTGTGTCTCAGGACTAAGAAACCCCTGGTTTGTAGTAGAAAAGGGCCTGGAAA 2116
 |||
 Db 1977 GAAGTGTCAACTGTGTCTCAGGACTAAGAAACCCCTGGTTTGTAGTAGAAAAGGGCCTGGAAA 2036
 |||

Qy 2117 GAGGGGAGCCAACAAATCTGTCTGCTTCTCATTAGTCATTGGCAATAAGCATTCTG 2176
 |||
 Db 2037 GAGGGGAGCCAACAAATCTGTCTGCTTCTCATTAGTCATTGGCAATAAGCATTCTG 2096
 |||

Qy 2177 TCTCTTTGGCTGCTGCCTCAGCAGAGAGCCAGAACTCTATCGGGCACCAGGATAACAT 2236
 |||
 Db 2097 TCTCTTTGGCTGCTGCCTCAGCAGAGAGCCAGAACTCTATCGGGCACCAGGATAACAT 2156
 |||

Qy 2237 CTCTCAGTGAACAGAGTTGACAAGGCCTATGGGAAATGCCTGATGGGATTATCTTCAGCT 2296
 |||
 Db 2157 CTCTCAGTGAACAGAGTTGACAAGGCCTATGGGAAATGCCTGATGGGATTATCTTCAGCT 2216
 |||

Qy 2297 TGTGAGCTTCTAAGTTTCTTCCCTTCATTCTACCCGCAAGCCAAGTTCTGTAAGAGA 2356
 |||
 Db 2217 TGTGAGCTTCTAAGTTTCTTCCCTTCATTCTACCCGCAAGCCAAGTTCTGTAAGAGA 2276
 |||

Qy 2357 AATGCCTGAGTTCTAGCTCAGGTTTCTTACTCTGAATTAGATCTCCAGACCCCTTCCTG 2416
 |||
 Db 2277 AATGCCTGAGTTCTAGCTCAGGTTTCTTACTCTGAATTAGATCTCCAGACCCCTTCCTG 2336
 |||

Qy 2417 GCCACAATTCAAATTAAGGCAACAACATATACCTTCCATGAAGCACACACAGACTTTTG 2476
 |||
 Db 2337 GCCACAATTCAAATTAAGGCAACAACATATACCTTCCATGAAGCACACACAGACTTTTG 2396
 |||

Qy 2477 AAAGCAAGGACAATGACTGCTTGAATTGAGGCCTTGAGGAATGAAGCTTTGAAGGAAAAG 2536
 |||
 Db 2397 AAAGCAAGGACAATGACTGCTTGAATTGAGGCCTTGAGGAATGAAGCTTTGAAGGAAAAG 2456
 |||

Qy 2537 AATACTTTGTTTCCAGCCCCCTTCCACACTCTTCATGTGTTAAACCACTGCCTTCTCTGGA 2596
 |||
 Db 2457 AATACTTTGTTTCCAGCCCCCTTCCACACTCTTCATGTGTTAAACCACTGCCTTCTCTGGA 2516
 |||

Qy 2597 CCTTGGAGCCACGGTGACTGTATTACATGTTGTTATAGAAAACATGATTTTAGAGTTCTGA 2656
 |||
 Db 2517 CCTTGGAGCCACGGTGACTGTATTACATGTTGTTATAGAAAACATGATTTTAGAGTTCTGA 2576
 |||

Qy 2657 TCGTTCAAGAGAATGATTAATATACATTTCTCTA 2690
 |||
 Db 2577 TCGTTCAAGAGAATGATTAATATACATTTCTCTA 2610
 |||

Claims 1-10 and 15-18 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Mitcham et al (U.S. Patent No. 6,468,546). Mitcham et al discloses a nucleic acid (SEQ ID NO: 391) that hybridizes to SEQ ID NO: 109 of the instant application (see the alignment below). Mitcham et al also teaches the use of the nucleic acid as a marker for ovarian cancer, treatment of ovarian cancer, and kits for the detection of ovarian cancer (*e.g.*, see the Abstract, column 8, lines 26-40, column 18, line 34 through column 19, line 51, column 24, lines 36-51, column 28, line 4 through column 29, line 45, and column 30, line 21 through column 33, line 5).

ALIGNMENT OF SEQ ID NO: 109 AND MITCHAM ET AL (U.S. Patent No. 6,468,546, SEQ ID NO: 391)

```

RESULT 1
US-09-404-879A-391
; Sequence 391, Application US/09404879A
; Patent No. 6468546
; GENERAL INFORMATION:
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: King, Gordon E.
; APPLICANT: Algate, Paul A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; TITLE OF INVENTION: DIAGNOSIS OF OVARIAN CANCER
; FILE REFERENCE: 210121.462C2
; CURRENT APPLICATION NUMBER: US/09/404,879A
; CURRENT FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 393
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 391
; LENGTH: 2627
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-404-879A-391

```

```

Query Match          90.5%; Score 2434; DB 3; Length 2627;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2434; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      257  CAGGGAGACACTCCATCACAGTCACTACTGTGCGCCTCAGCTGGGAACATTGGGGAGGATG 316
      |||
Db      177  CAGGGAGACACTCCATCACAGTCACTACTGTGCGCCTCAGCTGGGAACATTGGGGAGGATG 236

Qy      317  GAATCCTGAGCTGCACTTTTGAACCTGACATCAAACCTTTCGTGATCGTGATACAAATGGC 376

```

Art Unit: 1634

Db 237 GAATCCTGAGCTGCACCTTTTGAACCTGACATCAAACCTTTCTGATATCGTGATACAATGGC 296
 Qy 377 TGAAGGAAGGTGTTTTAGGCTTGGTCCATGAGTTCAAAGGAAGGCAAGATGAGCTGTGCG 436
 Db 297 TGAAGGAAGGTGTTTTAGGCTTGGTCCATGAGTTCAAAGGAAGGCAAGATGAGCTGTGCG 356
 Qy 437 AGCAGGATGAAATGTTTACAGAGGCCGAGCAGCAGTGTCTGCTGATCAAGTGATAGTTGGCA 496
 Db 357 AGCAGGATGAAATGTTTACAGAGGCCGAGCAGCAGTGTCTGCTGATCAAGTGATAGTTGGCA 416
 Qy 497 ATGCTCTTTGCGGGTGAAGAACGTGCAACTCACAGATGCTGGCAGCTACAAATGTTATA 556
 Db 417 ATGCTCTTTGCGGGTGAAGAACGTGCAACTCACAGATGCTGGCAGCTACAAATGTTATA 476
 Qy 557 TCATCACTTCTAAAGGCAAGGGGAATGCTAACCTTGAGTATAAACTGGAGCCTTCAGCA 616
 Db 477 TCATCACTTCTAAAGGCAAGGGGAATGCTAACCTTGAGTATAAACTGGAGCCTTCAGCA 536
 Qy 617 TGCCGGAAGTGAATGTGGACTATAATGCCAGCTCAGAGACCTTGCGGTGTGAGGCTCCCC 676
 Db 537 TGCCGGAAGTGAATGTGGACTATAATGCCAGCTCAGAGACCTTGCGGTGTGAGGCTCCCC 596
 Qy 677 GATGGTTCCCCCAGCCACAGTGGTCTGGGCATCCCAAGTTGACAGGGAGCCAACTTCT 736
 Db 597 GATGGTTCCCCCAGCCACAGTGGTCTGGGCATCCCAAGTTGACAGGGAGCCAACTTCT 656
 Qy 737 CGGAAGTCTCCAATACCAAGCTTTGAGCTGAACCTCTGAGAATGTGACCATGAAGTTGTGT 796
 Db 657 CGGAAGTCTCCAATACCAAGCTTTGAGCTGAACCTCTGAGAATGTGACCATGAAGTTGTGT 716
 Qy 797 CTGTGCTCTACAATGTTACGATCAACAACACATACTCCTGTATGATTGAAAATGACATTG 856
 Db 717 CTGTGCTCTACAATGTTACGATCAACAACACATACTCCTGTATGATTGAAAATGACATTG 776
 Qy 857 CCAAAGCAACAGGGGATATCAAAGTGACAGAATCGGAGATCAAAGGCCGAGTCACTTAC 916
 Db 777 CCAAAGCAACAGGGGATATCAAAGTGACAGAATCGGAGATCAAAGGCCGAGTCACTTAC 836
 Qy 917 AGCTGCTAAACTCAAAGGCTTCTCTGTGTCTCTCTTTCTTTTGGCCATCAGCTGGGCAC 976
 Db 837 AGCTGCTAAACTCAAAGGCTTCTCTGTGTCTCTCTTTCTTTTGGCCATCAGCTGGGCAC 896
 Qy 977 TTCTGCCTCTCAGCCCTTACCTGATGCTAAAAATATGTGCCTTGGCCACAAAAAGCATG 1036
 Db 897 TTCTGCCTCTCAGCCCTTACCTGATGCTAAAAATATGTGCCTTGGCCACAAAAAGCATG 956
 Qy 1037 CAAAGTCATTGTTACAACAGGGATCTACAGAATAATTTACCAACAGATATGACCTAGTT 1096
 Db 957 CAAAGTCATTGTTACAACAGGGATCTACAGAATAATTTACCAACAGATATGACCTAGTT 1016
 Qy 1097 TTATATTTCTGGGAGGAAATGAATTCATATCTAGAAGTCTGGAGTGAGCAACAAGAGCA 1156
 Db 1017 TTATATTTCTGGGAGGAAATGAATTCATATCTAGAAGTCTGGAGTGAGCAACAAGAGCA 1076
 Qy 1157 AGAAACAAAAAGAGCCAAAAGCAGAAGGCTCCAATATGAACAAGATAAATCTATCTTCA 1216
 Db 1077 AGAAACAAAAAGAGCCAAAAGCAGAAGGCTCCAATATGAACAAGATAAATCTATCTTCA 1136

	1217	AAGACATATTAGAAGTTGGGAAAATAATTCATGTGAACTAGACAAGTGTGTTAAGAGTGA	1276
Db	1137	AAGACATATTAGAAGTTGGGAAAATAATTCATGTGAACTAGACAAGTGTGTTAAGAGTGA	1196
Qy	1277	TAAGTAAATGCAAGTGGAGACAAGTGCATCCCAAGTCTCAGGGACCTCCCCCTGCCTG	1336
Db	1197	TAAGTAAATGCAAGTGGAGACAAGTGCATCCCAAGTCTCAGGGACCTCCCCCTGCCTG	1256
Qy	1337	TCACCTGGGGAGTGAGAGGACAGGATAGTGCATGTTCTTTTGTCTCTGAATTTTAGTTAT	1396
Db	1257	TCACCTGGGGAGTGAGAGGACAGGATAGTGCATGTTCTTTTGTCTCTGAATTTTAGTTAT	1316
Qy	1397	ATGTGCTGTAAAGTTGTCTGAGGAAGCCCTGGAAAGTCTATCCCAACATATCCACATC	1456
Db	1317	ATGTGCTGTAAAGTTGTCTGAGGAAGCCCTGGAAAGTCTATCCCAACATATCCACATC	1376
Qy	1457	TTATATTCCACAAATTAAGCTGTAGTATGTACCTTAAGACGCTGCTAATTGACTGCCACT	1516
Db	1377	TTATATTCCACAAATTAAGCTGTAGTATGTACCTTAAGACGCTGCTAATTGACTGCCACT	1436
Qy	1517	TCGCAACTCAGGGGCGGCTGCATTTTAGTAATGGGTCAAAATGATTCACCTTTTATGATGC	1576
Db	1437	TCGCAACTCAGGGGCGGCTGCATTTTAGTAATGGGTCAAAATGATTCACCTTTTATGATGC	1496
Qy	1577	TTCCAAAGGTGCCTTGGCTTCTCTTCCCAACTGACAAATGCCAAAGTTGAGAAAAATGAT	1636
Db	1497	TTCCAAAGGTGCCTTGGCTTCTCTTCCCAACTGACAAATGCCAAAGTTGAGAAAAATGAT	1556
Qy	1637	CATAATTTTAGCATAAACAGACAGTCGGCGACACCGATTTTATAAAATAACTGAGCACC	1696
Db	1557	CATAATTTTAGCATAAACAGACAGTCGGCGACACCGATTTTATAAAATAACTGAGCACC	1616
Qy	1697	TTCTTTTAAACAAACAAATGCGGGTTTATTTCTCAGATGATGTCATCCGCGAATGGTC	1756
Db	1617	TTCTTTTAAACAAACAAATGCGGGTTTATTTCTCAGATGATGTCATCCGCGAATGGTC	1676
Qy	1757	CAGGGAAGGACCTTTCACCTTGACTATATGGCATTATGTCAACAAAGCTCTGAGGGCTTC	1816
Db	1677	CAGGGAAGGACCTTTCACCTTGACTATATGGCATTATGTCAACAAAGCTCTGAGGGCTTC	1736
Qy	1817	TCCTTTCCATCCTCGCTGGACAGCTAAGACCTCAGTTTTCATAGCATCTAGAGCAGTGG	1876
Db	1737	TCCTTTCCATCCTCGCTGGACAGCTAAGACCTCAGTTTTCATAGCATCTAGAGCAGTGG	1796
Qy	1877	GACTCAGCTGGGGTGATTTGCGCCCCCATCTCCGGGGGAATGTCGGAAGACAATTTTGGT	1936
Db	1797	GACTCAGCTGGGGTGATTTGCGCCCCCATCTCCGGGGGAATGTCGGAAGACAATTTTGGT	1856
Qy	1937	TACCTCAATGAGGGAGTGAGGAGGATACAGTGCTACTACCAACTAGTGGATAAAGGCCA	1996
Db	1857	TACCTCAATGAGGGAGTGAGGAGGATACAGTGCTACTACCAACTAGTGGATAAAGGCCA	1916
Qy	1997	GGGATGCTGCTCAACCTCCTACCATTGACAGGACGCTCTCCCAATTACAACATACCAATCC	2056
Db	1917	GGGATGCTGCTCAACCTCCTACCATTGACAGGACGCTCTCCCAATTACAACATACCAATCC	1976
Qy	2057	GAAGTGTCAACTGTGTCAAGACTAAGAAAACCTGGTTTGTAGTAGAAAAGGCGCTGGAAA	2116
Db	1977	GAAGTGTCAACTGTGTCAAGACTAAGAAAACCTGGTTTGTAGTAGAAAAGGCGCTGGAAA	2036

Art Unit: 1634

Qy 2117 GAGGGGAGCCAACTCTGTCTGCTTCCTCACATTAGTCATTGGCAATAAGCATTCTG 2176
 |||
 Db 2037 GAGGGGAGCCAACTCTGTCTGCTTCCTCACATTAGTCATTGGCAATAAGCATTCTG 2096
 |||

Qy 2177 TCTCTTTGGCTGCTGCCTCAGCACAGAGAGCCAGAACTCTATCGGGCACCAGGATAACAT 2236
 |||
 Db 2097 TCTCTTTGGCTGCTGCCTCAGCACAGAGAGCCAGAACTCTATCGGGCACCAGGATAACAT 2156
 |||

Qy 2237 CTCTCAGTGAACAGAGTTGACAAGGCCATATGGGAAATGCCTGATGGGATTATCTTCAGCT 2296
 |||
 Db 2157 CTCTCAGTGAACAGAGTTGACAAGGCCATATGGGAAATGCCTGATGGGATTATCTTCAGCT 2216
 |||

Qy 2297 TGTTGAGCTTCTAAGTTTCTTTCCCTTCATTCTACCTGCAAGCCAAGTTCTGTAAGAGA 2356
 |||
 Db 2217 TGTTGAGCTTCTAAGTTTCTTTCCCTTCATTCTACCTGCAAGCCAAGTTCTGTAAGAGA 2276
 |||

Qy 2357 AATGCCTGAGTCTAGCTCAGGTTTTCTTACTCTGAATTTAGATCTCCAGACCCCTTCCTG 2416
 |||
 Db 2277 AATGCCTGAGTCTAGCTCAGGTTTTCTTACTCTGAATTTAGATCTCCAGACCCCTTCCTG 2336
 |||

Qy 2417 GCCACAATTCAAATTAAGGCAACAACATATACCTTCCATGAAGCACACACAGACTTTTG 2476
 |||
 Db 2337 GCCACAATTCAAATTAAGGCAACAACATATACCTTCCATGAAGCACACACAGACTTTTG 2396
 |||

Qy 2477 AAAGCAAGGACAATGACTGCTTGAATTGAGGCCTTGAGGAATGAAGCTTTGAAGGAAAAG 2536
 |||
 Db 2397 AAAGCAAGGACAATGACTGCTTGAATTGAGGCCTTGAGGAATGAAGCTTTGAAGGAAAAG 2456
 |||

Qy 2537 AATACTTTGTTTCCAGCCCCCTTCCACACTCTTCATGTGTTAACCAGTGCCTTCCTGGA 2596
 |||
 Db 2457 AATACTTTGTTTCCAGCCCCCTTCCACACTCTTCATGTGTTAACCAGTGCCTTCCTGGA 2516
 |||

Qy 2597 CCTTGGAGCCACGGTGACTGTATTACATGTTGTATAGAAAAGTATTTAGAGTTCTGA 2656
 |||
 Db 2517 CCTTGGAGCCACGGTGACTGTATTACATGTTGTATAGAAAAGTATTTAGAGTTCTGA 2576
 |||

Qy 2657 TCGTTCAAGAGAATGATTAAATATACATTTCCTA 2690
 |||
 Db 2577 TCGTTCAAGAGAATGATTAAATATACATTTCCTA 2610
 |||

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Martinell whose telephone number is (571) 272-0719.

The examiner works a flexible schedule and can be reached by phone and voice mail.

Alternatively, a request for a return telephone call may be e-mailed to james.martinell@uspto.gov. Since e-mail communications may not be secure, it is suggested that information in such requests be limited to name, phone number, and the best time to return the call.

Art Unit: 1634

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735.

OFFICIAL FAX NUMBER

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Any Official Communication to the USPTO should be faxed to this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/James Martinell/
Primary Examiner
Art Unit 1634